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PURPOSE. Few studies have explored the association of genetic variants in microRNA genes and
binding sites with diabetic retinopathy (DR) in type 1 diabetes. We conducted a genome-wide
scan for single nucleotide polymorphisms (SNPs) in these genes by using data from a genome-
wide association study (GWAS).
METHODS. All known SNPs were imputed from our GWAS data (n ¼ 325) of DR cases and
diabetic controls (no DR). Relevant SNPS were extracted using miRNASNP and PolymiRTS
(version 2) databases. v2 tests and logistic regression (adjusting for age, sex, duration of
diabetes, HbA1c, and hypertension) were used to test the association between the imputed
SNPs and DR phenotypes (any DR, nonproliferative DR [NPDR], proliferative DR [PDR],
diabetic macular edema [DME], and sight-threatening DR defined as PDR, severe NPDR, or
clinically significant macula edema [CSME]) compared with diabetic controls. Top-ranking
SNPs were genotyped in a larger cohort (N ¼ 560) to confirm their association with DR.
RESULTS. Three SNPs (rs10061133, rs1049835, rs9501255) were selected and genotyped in the
final cohort. Rs10061133 in MIR449b was protective of sight-threatening DR (odds ratio [OR]
¼ 0.32, P ¼ 3.68 3 104) and PDR (OR ¼ 0.30, P ¼ 8.12 3 104), and the associations
became more significant as the cohort increased in size.
CONCLUSIONS. Rs10061133 in MIR449b is significantly associated with a decreased risk of PDR
and sight-threatening DR in Caucasian patients with type 1 diabetes. This can guide future
studies on genetic risk profiling and on developing microRNA-related therapies for sight-
threatening DR.
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Diabetic retinopathy (DR) is a leading cause of visual lossdue to damage to the retina from diabetes. It is a common
complication of type 1 diabetes, with a prevalence of 50% to
80%.1 The incidence of type 1 diabetes, and therefore diabetes-
related vision loss, is increasing at a rate of 3% to 5% per year.2
Type 1 diabetes is caused by immune-mediated destruction
of insulin-secreting beta cells of the pancreas. Genetic and
environmental factors influence the development and progres-
sion of the disease and its complications. DR in type 1 diabetes
has been demonstrated to have the highest sibling recurrence
risk of all the microvascular complications in a large study of
8114 type 1 diabetics among 6707 families.3 The genes that
contribute to DR risk are not well understood.4
Over the last 20 years, our understanding of the role of
microRNAs in disease has developed. MicroRNAs are short,
single-stranded RNA molecules that are involved in regulating
gene expression and are believed to modulate the expression of
one third of the genes in the genome.5 A single microRNA may
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bind to hundreds of genes and induce mRNA degradation or
translational repression. Genetic variations in microRNA genes
and their target binding sites can have significant consequenc-
es for these regulatory pathways. MicroRNAs have been
implicated in a wide range of diseases, including cancer and
cardiovascular and neurodegenerative diseases.6–8
Recently, differentially expressed microRNAs have been
found to be associated with DR,9 as well as other microvascular
diabetic complications.10 Few studies have explored whether
genetic variations in microRNA-related genes are associated
with DR. We previously studied microRNA 146a because of its
involvement in the NF-kB inflammatory pathways and identi-
fied functional polymorphism rs2910164 as being significantly
associated with diabetic macular edema (DME) in type 2
diabetes but not type 1 diabetes.11
In this study, we investigated the association of all known
microRNA genetic variations with DR in type 1 diabetes using a
large Australian and British Caucasian population. We first
performed an in silico study using imputed data from our
previously described genome-wide association study (GWAS)
for DR.12 We then confirmed the association of significant
genetic variants with DR by genotyping a large population that
included the original GWAS participants.
METHODS
Ethics Statement
This project was approved by the human research ethics
committees (HRECs) in Australia (Southern Adelaide Clinical
HREC, Royal Adelaide Hospital HREC, The Queen Elizabeth
Hospital [Adelaide] HREC, Royal Melbourne Hospital HREC,
Royal Victorian Eye and Ear Hospital HREC, St. Vincent’s
Hospital [Melbourne] HREC, South Eastern Sydney Illawarra
HREC, Tasmania Health and Medical HREC, Canberra Hospital
HREC) and the NHS Health Research Authority in London. It
adheres to the tenets of the Declaration of Helsinki. Written
informed consent was obtained from each participant before
study enrollment.
Recruitment of Patients and Data Collection
This study involved Caucasian participants (identifying as of
European descent) recruited in the Australian Registry of
Advanced Diabetic Retinopathy (RADAR) and the Genetic
Study of Diabetic Retinopathy based at Flinders University,
South Australia. Multiple recruitment centers were involved
and included the following Australian hospitals: Flinders
Medical Centre, The Repatriation General Hospital, The Royal
Adelaide Hospital, The Queen Elizabeth Hospital, The Royal
Melbourne Hospital, Royal Victorian Eye and Ear Hospital, St.
Vincent’s Hospital, Sydney Eye Hospital, Canberra Hospital,
Royal Hobart Hospital, and from the United Kingdom, The
National Institute for Health Research Biomedical Research
Centre at Moorfields Eye Hospital NHS Foundation Trust and
UCL Institute of Ophthalmology.
Eligible participants were actively recruited from ophthal-
mology, diabetes, and renal clinics, with the following
inclusion criteria: previous diagnosis of type 1 diabetes and
at least 18 years of age. All participants underwent a
questionnaire and venous blood sample collection for DNA
analysis. Clinical information was collected from case notes
and electronic records, including hemoglobin A1c (HbA1c),
renal, and lipid measures; medications; and the presence of
hypertension and nonocular diabetic complications. HbA1c
was recorded as the average of the three most recent available
measurements or of three measurements immediately prior to
a diagnosis of proliferative diabetic retinopathy (PDR).
Hypertension was defined as systolic and diastolic blood
pressure greater than 140 and 90 mm Hg, respectively, or
pharmacological treatment for hypertension. DR grading
(defined as the worst ever grading) and the presence of DME
were determined from documented dilated fundus examina-
tions performed by an ophthalmologist. DR grading was
defined by the International Clinical DR Severity Scale.13 No
DR was defined as no abnormalities found on dilated fundus
examination. PDR was defined as neovascularization, vitreous,
or preretinal hemorrhage. Other abnormalities between those
two stages were defined as nonproliferative DR (NPDR). Severe
NPDR was defined as any of the following: more than 20
intraretinal hemorrhages in all four quadrants of the retina,
venous beading in at least two quadrants, or prominent
microvascular abnormalities in at least one quadrant. Clinically
significant macular edema (CSME) was defined according to
the Early Treatment in Diabetic Retinopathy Study protocol.14
Sight-threatening DR was defined as severe NPDR, PDR, or
CSME. Only individuals with complete clinical information
were included in the analyses.
For each participant, approximately 8 mL blood was
collected in EDTA blood collection tubes and underwent
DNA extraction using a kit (QIAamp Blood DNA Maxi Kit;
Qiagen, Venlo, The Netherlands). Details regarding the data
collection method have been described previously.15
In Silico Analysis of MicroRNA Single Nucleotide
Polymorphisms (SNPs) in the Type 1 Diabetes
Discovery Cohort
A genome-wide association study has been previously per-
formed on 354 type 1 diabetic participants. Genotyping was
conducted with a kit (OmniExpress Array; Illumina, San Diego,
CA, USA) as described previously.12 The overall study design is
illustrated in Supplementary Fig. S1. Following data cleaning,
principal components were calculated using EIGENSTRAT
software, and individuals were removed if they were further
than six standard deviations from the mean of any principal
component, limiting the analysis to participants of predomi-
nantly European descent. Additional outliers were removed
based on visualizing the plot of PC1 versus PC2 (Supplemen-
tary Fig. S2). Relatedness was calculated using PLINK, a whole
genome data analysis toolset, and one of each pair with pi HAT
> 0.2 were removed. After quality control, a total of 325
samples remained. The autosomal genotype data were phased
using Eagle software (version 2.3.5),14 and genotypes were
then imputed on the basis of the 1000 Genomes Project
reference panel (EUR reference, Phase III, version 5)15 using
Minimac3 genotype imputation software (version 2.0.1).16
Indels, SNPs within 5 bp of an indel, rare variants (minor allele
frequency [MAF] < 0.01), and variants with poor imputation
quality (R2 < 0.8) were removed. Known microRNA genes and
their binding sites were downloaded from the miRNASNP and
PolymiRTS (version 2) databases (accessed August 31, 2017)
and used to filter the imputed SNPs.
The most likely genotype was used for the association
analyses with the imputed SNPs. Association tests with DR
phenotypes were performed in PLINK (version 1.07). Controls
were defined as those with diabetes but no DR. Analysis for
association with DR phenotypes was repeated for different
definitions of cases: (1) any DR, (2) PDR, (3) DME, and (4)
sight-threatening DR (severe NPDR, PDR, or CSME). Logistic
regression for multivariate analysis incorporated age, sex,
duration of diabetes, HbA1c, and hypertension. A quantile-
quantile plot of the P values in the association study for any DR
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compared with no DR in the GWAS discovery cohort is shown
in Supplementary Figure S3.
Stage 2 Genotyping and Combined Analysis
Top-ranking SNPs were selected for genotyping in stage 2 to
confirm that their association with DR as a two-stage design
with joint analysis is both cost effective and more powerful
than discovery and replication.17 For variations in microRNA
genes, SNPs were selected if P < 0.01 in the imputed data, and
for variations in microRNA binding sites, SNPs were selected if
P < 0.0001. All SNPs chosen had minor allele frequencies
greater than 1% in the imputed data.
Selected SNPs were genotyped in the total sample (N¼560)
by the Australian Genome Research Facility, using the
MassARRAY platform (Agena Bioscience, San Diego, CA,
USA). The same statistical analyses as described above were
performed: firstly, in the original GWAS group (n ¼ 325) to
validate the analysis with the imputation results, secondly with
the additional samples (n¼ 235) for replication, and thirdly in
all samples combined (N¼560) to maximize the study’s power
in the two-stage design.
RESULTS
Demographic details of the total study population stratified by
DR phenotype are shown in Table 1 for no DR and any DR, and
Supplementary Table S1 for PDR, DME, and sight-threatening
DR. As expected, diabetes duration and HbA1c increased as the
severity of DR increased, and this was significantly different
between cases and controls.
In the discovery cohort, 2420 SNPs in microRNA genes and
401,000 SNPs in microRNA binding sites of target genes were
retrieved from the imputed SNP data (n¼ 325 type 1 diabetes
patients). After quality control, 213 microRNA variants and
41,578 microRNA binding site variants remained. Nominal
associations between these microRNA SNPs and DR pheno-
types (P < 0.05) are shown in Supplementary Data File S1.
Nominal associations between microRNA binding site SNPs
and DR phenotypes (P < 0.05) are shown in Supplementary
Data File S2. No SNPs reached significance after multiple
hypothesis testing (41,791 variants, four outcomes, P < 3.003
107). The top SNPs across the phenotypes were therefore
selected for genotyping. Notably, the top-ranked SNP for sight-
threatening DR, rs10061133 in MIR449b, is also highly ranked
in the analysis of PDR. No additional SNPs in the DME group
reached our significance criteria for further genotyping, and
this is likely because the numbers are very small (n¼ 48).
A total of eight SNPs in microRNA genes and microRNA
binding sites were selected for genotyping, however only three
(one in a microRNA gene and two in binding sites) were
successfully genotyped in the final study population:
rs10061133 (MIR449), rs9501255 (HLA-DPB1), and
rs1049835 (GPM6A). Table 2 shows the number of individuals
in each stage of analysis and with each phenotype.
Two of the three SNPs were associated with a DR
phenotype after multivariable analysis (adjusting for age, sex,
duration of diabetes, HbA1c, and hypertension) of the
genotyped data in the original discovery cohort (Table 3).
The lack of validation of rs9501255 in HLA-DPB1 suggests the
imputation of this SNP was of poor quality, as is often seen
with HLA SNPs. Of the two remaining SNPs associated with
sight-threatening DR in the discovery cohort, neither were
associated with sight-threatening DR (P > 0.05) in the
additional samples genotyped (n ¼ 235). When all samples
were combined, rs10061133 (MIR449b) and rs1049835
(GPM6A) were associated with sight-threatening DR (Table
3). Rs1006113 (MIR449b) in particular became more signifi-
cantly associated with sight-threatening DR as the sample size
increased (P ¼ 3.68 3 104) and showed consistent OR
between the discovery and the additional samples (Table 3).
This SNP was protective against sight-threatening DR with an
OR of 0.31 to 0.37 across the three stages.
The two associated SNPs (rs10061133 and rs1049835) were
then analyzed for association with DME and subtypes of sight-
threatening DR (PDR and CSME) in the final combined sample.
Rs10061133 in MIR449b was strongly associated with a
decreased risk of PDR (OR ¼ 0.30, 95% CI 0.15–0.61, P ¼
8.123 104) but not the other phenotypes.
DISCUSSION
In our discovery cohort, no SNPs reached significance after
multiple hypothesis testing (P < 3.00 3 107). Therefore, we
undertook a two-stage design, selecting the top-ranking SNP
for evaluation in the second cohort and a combined analysis
between the two. The two-stage design with joint analysis is
both cost effective and more powerful than discovery and
replication.17 We found that rs10061133 in MIR449b was most
consistently associated with sight-threatening DR and PDR.
The minor allele G was protective against sight-threatening DR
and PDR after adjustment for covariates and was confirmed
with greater significance in the larger sample. A large
proportion of the sight-threatening DR group consisted of
PDR samples (181 out of 223), and thus this association is
likely to be more important in PDR risk, rather than CSME.
Rs10061133 in MIR449b has been reported to be associated
with other diseases such as esophageal cancer,18 thyroid
TABLE 1. Demographics of Total Study Population Stratified Between No DR and Any DR
Demographic No DR Any DR P Value
n 228 332
Female, n (%) 99 (43.8) 178 (47.3) 0.44
Age, y, median (range) 34 (17–83) 47 (18–88) 3.33 3 1022
Diabetes duration, y, median (range) 13 (5–60) 28 (5–70) 7.57 3 1049
HbA1c, %, median (range) 8.06 (5–15) 8.6 (5–15) 4.00 3 106
Hypertension, n (%) 53 (23.5) 225 (59.8) 2.26 3 1018
TABLE 2. Number of Individuals in Each Stage of Analysis by
Phenotype Included in Logistic Regression Analysis
Discovery
Cohort
Additional
Cohort Total
No DR 123 105 228
Any DR 202 130 332
DME 48 41 89
PDR 125 56 181
Sight-threatening DR 155 68 223
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cancer,19 premature ovarian insufficiency,20 and recurrent
pregnancy loss.21 To our knowledge, this is the first study to
report an association between rs10061133, microRNA 449b,
and DR in type 1 diabetes.
Few studies have explored microRNA involvement in DR.
Kovacs et al.9 reported 86 differentially expressed microRNA in
retinal endothelial cells of streptozotocin-induced diabetic rats.
The majority of these were NF-jB, VEGF, and p53 responsive
and included microRNA 449a but not microRNA 449b. Other
studies have compared expression levels of microRNA in
serum between cases and controls using microRNA arrays.22–24
These studies were small, and only one study has been
performed in type 1 diabetes. Barutta et al.25 found 25
differentially expressed microRNAs between 312 diabetic
complication cases and 143 diabetic controls in type 1
diabetes. Specifically, microRNA 126 levels were negatively
associated with proliferative retinopathy (0.77 vs. 1.29, P ¼
0.02). Studies profiling microRNA using microarrays have
identified microRNA 21, 200b, 15a, 320a, 320b, 93, 29a, and
423-5p to be significantly associated with proliferative disease
in both types of diabetes.26–28
MicroRNA 449b is part of a family of microRNAs with
similar sequences and secondary structures including micro-
RNA 449a, 449c, and 38. They are all involved in cell
proliferation, tumorigenesis, and angiogenesis and are impor-
tantly hypoxia-regulated microRNAs. MicroRNA 449a and 449b
have been found in retinal tissues of mice.29,30 In an oxygen-
induced DR mouse model, microRNA 449a was significantly
downregulated, which is in keeping with a protective role
against DR.30 MicroRNA 449b has not been reported in human
vitreous; however, the studies investigating vitreous micro-
RNAs are few, and a small number of specimens (fewer than
five PDR samples) have been analyzed.26–28 The angiogenesis
pathway that microRNA 449b regulates is the E2F pathway.31
E2F is a transcription factor essential for cell proliferation. E2F
increases the levels of microRNA449b that then inhibit E2F in a
negative feedback loop. Activation of E2F regulates the
expression of other genes involved in angiogenesis, such as
VEGF and PIGF and breakdown of the blood-retinal barrier
such as E-cadherin, and hence there is good biological
plausibility for the involvement of microRNA 449b in DR
susceptability.32,33 Another downstream target of microRNA
449a/b is SERPINE1, also known as plasminogen activator
inhibitor-1 (PAI-1). Under hypoxic conditions, downregulation
of microRNA 449a/b increases expression levels of PAI-1.34 The
main role of PAI-1 is to inhibit fibrinolysis, but it has also been
shown to play an important role in facilitating retinal
angiogenesis.35 PAI-1 levels are increased in the serum of DR
patients compared with diabetic controls,36 and polymor-
phisms of the PAI-1 gene have been previously linked with
DR.37
Polymorphisms of microRNA genes can affect either the
seed region (binding site) or the processing of precursor
microRNA to mature microRNA and therefore the overall
production and function of the molecule. Evidence supporting
this has largely come from bioinformatics and statistical
analyses.38 Rs10061133 is a single nucleotide polymorphism,
where the replacement of G over A in the MIR449b gene is
predicted to alter a Dicer cleavage site according to the miRvar
database.39 Dicer is the enzyme that cleaves the precursor
microRNA to the mature form. Therefore, rs10061133 could
have functional consequences on microRNA449b through this
mechanism. Further functional studies are required to explore
this hypothesis.
Despite our intention to comprehensively study all known
microRNA variants, some microRNAs could not be studied. We
attempted to study 2420 known microRNA gene variants and
401,000 microRNA binding site variants, but only 213 andT
A
B
L
E
3
.
V
al
id
at
io
n
an
d
R
e
p
li
c
at
io
n
o
f
A
ss
o
c
ia
ti
o
n
R
e
su
lt
s
S
N
P
G
e
n
e
M
in
o
r
A
ll
e
le
D
R
C
a
se
P
h
e
n
o
ty
p
e
D
is
co
v
e
ry
,
Im
p
u
te
d
D
is
c
o
v
e
ry
,
G
e
n
o
ty
p
e
d
A
d
d
it
io
n
a
l
G
e
n
o
ty
p
e
d
A
ll
S
a
m
p
le
s
C
o
m
b
in
e
d
M
A
F
C
a
se
s
v
s.
C
o
n
tr
o
ls
O
R
9
5
%
C
I
P
V
a
lu
e
M
A
F
C
a
se
s
v
s.
C
o
n
tr
o
ls
O
R
9
5
%
C
I
P
V
a
lu
e
M
A
F
C
a
se
s
v
s.
C
o
n
tr
o
ls
O
R
9
5
%
C
I
P
V
a
lu
e
M
A
F
C
a
se
s
v
s.
C
o
n
tr
o
ls
O
R
9
5
%
C
I
P
V
a
lu
e
rs
1
0
0
6
1
1
3
3
M
IR
4
4
9
B
G
Si
g
h
t-
th
re
at
e
n
in
g
D
R
0
.0
8
v
s.
0
.1
4
0
.3
6
(0
.1
7
–
0
.7
4
)
5
.3
2
3
1
0

3
0
.0
7
v
s.
0
.1
4
0
.3
1
(0
.1
5
–
0
.6
5
)
1
.6
3
3
1
0

3
0
.0
8
v
s.
0
.1
0
0
.3
7
(0
.1
0
–
1
.3
6
)
0
.1
3
0
.0
8
v
s.
0
.1
3
0
.3
2
(0
.1
7
–
0
.6
0
)
3
.6
8
3
1
0

4
rs
1
0
4
9
8
3
5
G
P
M
6
A
G
Si
g
h
t-
th
re
at
e
n
in
g
D
R
0
.4
2
v
s.
0
.2
7
2
.3
2
(1
.5
7
–
3
.4
4
)
2
.4
0
3
1
0

5
0
.4
2
v
s.
0
.2
7
2
.1
7
(1
.3
8
–
3
.4
3
)
8
.6
3
3
1
0

4
0
.2
7
v
s.
0
.3
6
1
.1
5
(0
.5
9
–
2
.2
5
)
0
.6
8
0
.3
7
v
s.
0
.3
1
1
.7
2
(1
.2
0
–
2
.4
8
)
3
.5
2
3
1
0

3
rs
9
5
0
1
2
5
5
H
L
A
-D
P
B
1
T
A
n
y
D
R
0
.0
2
v
s.
0
.0
7
0
.1
3
(0
.0
5
–
0
.3
6
)
6
.1
0
3
1
0

5
0
.0
2
v
s.
0
.0
8
0
.2
6
(0
.2
2
–
0
.8
6
)
0
.0
1
7
0
.0
3
v
s.
0
.0
2
1
.7
7
(0
.3
9
–
8
.0
7
)
0
.4
6
0
.0
2
v
s.
0
.0
5
0
.4
2
(0
.1
7
–
1
.0
0
)
0
.0
5
0
P
v
al
u
e
an
d
O
R
w
it
h
9
5
%
C
I
ar
e
g
iv
e
n
fo
r
al
l
su
c
c
e
ss
fu
ll
y
ge
n
o
ty
p
e
d
SN
P
s
at
e
ac
h
st
ag
e
o
f
th
e
an
al
ys
is
in
c
lu
d
in
g
b
o
th
th
e
im
p
u
ta
ti
o
n
an
d
g
e
n
o
ty
p
in
g
o
f
th
e
d
is
c
o
ve
ry
c
o
h
o
rt
al
o
n
g
w
it
h
th
e
ad
d
it
io
n
al
sa
m
p
le
s
ge
n
o
ty
p
e
d
an
d
th
e
c
o
m
b
in
e
d
c
o
h
o
rt
.
A
ll
an
al
ys
e
s
ar
e
ad
ju
st
e
d
fo
r
ag
e
,
se
x
,
d
u
ra
ti
o
n
o
f
d
ia
b
e
te
s,
H
b
A
1
c
,
an
d
h
yp
e
rt
e
n
si
o
n
.
C
I,
c
o
n
fi
d
e
n
c
e
in
te
rv
al
;
O
R
,
o
d
d
s
ra
ti
o
;
M
A
F,
m
in
o
r
al
le
le
fr
e
q
u
e
n
c
y.
MicroRNA Genes, Diabetic Retinopathy, and Type 1 Diabetes IOVS j September 2019 j Vol. 60 j No. 12 j 3940
41,578 SNPs, respectively, were imputed with good quality.
While we had many type 1 diabetic participants from our
registry, after stratifying the group into different phenotypes,
the numbers for analyses were much smaller. This clearly limits
the scope of the current study. Future work should focus on
directly genotyping microRNA SNPs in a suitably powered
cohort, with replication in independent cohorts. Some of the
top-ranked SNPs in microRNA genes also failed genotyping in
the replication dataset. It is possible that as microRNAs form
secondary structures, the DNA template could have also
formed secondary structures during the PCR stage and
potentially inhibited primer binding. This study could be
strengthened by analysis of miRNAs in biological tissues (such
as plasma/serum) of patients with type 1 diabetes; however, as
the genetic association results do not reach significance after
multiple hypotheses testing (P < 3.00 3 107), the results
should be replicated by independent studies before resources
are directed to functional assays. Interpretation of genetic
associations is also complicated by the clinical picture of DR.
Age and duration of diabetes are significant risk factors for
worsening DR, resulting in the selection of a younger and
healthier control group. We have corrected for hypertension,
given its strong association with DR, but have not adjusted for
other comorbidities, such as hyperlipidemia or macrovascular
complications (e.g., heart disease). Strengths of this study
include sample population from multiple sites, rigor of DR
status characterization and categorization, analyses with
adjustments for known clinical risk factors, and meta-analyses
after a two-stage design.
CONCLUSIONS
Through a genome-wide approach, we have identified novel
microRNA and microRNA binding site genetic variants
associated with DR phenotypes in a large Caucasian population
of type 1 diabetic participants. Rs10061133 in MIR449b was
found to be strongly and consistently associated with sight-
threatening DR and PDR, when compared with diabetic
controls (no DR), although independent replication is
required. Bioinformatics predict rs10061133 has functional
consequences on microRNA449b and therefore can affect
regulation of inflammatory pathways in DR. These results have
helped elucidate the complex genetic mechanisms involved in
DR susceptibility in type 1 diabetes and can guide future
studies on genetic risk profiling and developing microRNA-
related therapies for sight-threatening DR.
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